1,715
Participants
Start Date
July 22, 2014
Primary Completion Date
October 2, 2015
Study Completion Date
October 2, 2015
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
0.5 milliliter (mL), Intramuscular (IM)
Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
0.5 mL, IM
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
0.5 mL, IM
GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
0.5 mL, IM
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
0.5 mL, Intramuscular (IM)
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
0.5 mL, IM
GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
0.5 mL, IM
Erie
Columbia
Charlottesville
Midlothian
Charleston
Miami Beach
Birmingham
Huntsville
Tullahoma
Kingsport
Bardstown
Nicholasville
Cleveland
Dayton
Wichita
Lincoln
Lincoln
Lincoln
Norman
Layton
Orem
Provo
Roy
Syracuse
West Jordan
South Jordan
Salt Lake City
Salt Lake City
West Haven
Payson
Spanish Fork
Downey
San Diego
Spokane
Spokane
San Juan
Sanofi Pasteur, a Sanofi Company
INDUSTRY